Report updated May 19, 2026
Shotsy GLP-1 Tracker
For individuals prescribed GLP-1 receptor agonists for weight management or type 2 diabetes requiring precise dose tracking.
Shotsy GLP-1 Tracker is a well-regarded health & fitness app that is available. With a 4.8/5 rating from 23.2K reviews, it maintains solid user satisfaction. Users particularly appreciate estimated medication level charts provide actionable insights for managing injection schedules and symptoms, though paywalling previously free features like medication level charts creates friction for long-term users remains a common concern.
What is Shotsy GLP-1 Tracker?
Shotsy is a specialized medication tracker for GLP-1 weight loss and diabetes patients, providing dose scheduling and clinical-data visualizations on iOS.
Users hire Shotsy to manage the complexity of multi-drug injection schedules and visualize medication levels, which standard calorie trackers fail to address.
Current Momentum
v3.0 · 6d ago
Active- Shipped chart interaction and logging fixes.
- Transitioned core features to subscription model.
Active Nemesis
Lose It! – Calorie Counter
By FitNow
Other Rivals
7-Day Rank Pulse 🇺🇸
Health & FitnessNo ranking data
Rating Pulse 🇺🇸
Recent User Mood
What makes this app unique?
What Are The Key Features?
Visualizes medication concentration over time using peer-reviewed clinical data.
Supports simultaneous tracking of multiple GLP-1 injections and daily oral pills.
Automates data import for weight, calories, protein, and water intake.
How much does it cost?
- Free access to basic logging
- Subscription for advanced analytics and medication levels
Transitioning from a free tool to a subscription model has created significant friction with long-term users.
Who Built It?
Empowering GLP-1 medication users with data-driven tracking and clinical visualization tools to manage their weight-loss journey.
Portfolio
2
Apps
What other apps does Shotsy make?
Shotsy - GLP-1 Tracker
Explore the full Shotsy report
Portfolio breakdown, audience, momentum, and every app published by Shotsy.
What do users think recently?
High confidence · Latest 84 of 98 total reviews analyzed · Based on 98 reviews. Signal may be noisy.
How did the latest release land?
What is the recent mood?
Recent user voice shows a excited sentiment. Users appreciate estimated medication level charts provide actionable insights for managing injection schedules and symptoms, but report paywalling previously free features like medication level charts creates friction for long-term users.
What Users Love
What Frustrates Users
What Users Want
How have ratings & review volume moved?
Rating, review sentiment, and total reviews over time, with release markers showing the post-launch impact.
Vertical markers = app releases. Hover any release for the post-release impact delta.
View the full user-sentiment analysis
Mood gauge, ratings & review-volume history, every praise / complaint / request, and sentiment over time.
What is the competitive landscape for Shotsy GLP-1 Tracker?
Where is it available?
Localized markets (20)
How's The Health & Fitness Market?
How does it evolve in the Health & Fitness market?
Shotsy holds a #80 Grossing rank in the US Health & Fitness category, with international growth evidenced by a #25 Grossing rank in Uruguay. The gap between its utility-driven retention and the recent subscription-gate friction suggests a need to re-align monetization with user value.
Rank progression
86 active rankings tracked — 30-day window
Which niche is Shotsy GLP-1 Tracker in?
to track medication doses and health progress
Explore the full Diabetes Management Trackers niche
Every app in this space — 46 tracked, the niche's live rankings, and Marlvel's editorial take on the job-to-be-done.
The rivals identified
Nemeses(1)
NimbleRx competes for the same GLP-1 user base by capturing the pharmacy fulfillment and medication management lifecycle that Shotsy users must navigate.
Contenders(4)
WellView competes by offering pharmacy-specific utility, specifically targeting the cost and acquisition of medications for chronic conditions.
This app competes for the attention of users who prioritize visual progress reporting and trend analysis of their metabolic markers.
Walmart competes by owning the physical supply chain for GLP-1 medications, making it a destination for users who need to manage refills.
This app targets the same chronic condition management audience, focusing on the physiological data that GLP-1 users often need to track alongside their doses.
Same space(3)
Stelo competes by offering hardware-backed biosensor data, providing a more scientific approach to metabolic health than manual logging.
This app competes on modern UX and platform-native features, appealing to users who want high-visibility tracking on their home screens.
A long-standing incumbent in the diabetes tracking space, it competes for the same user base that requires both medication and glucose monitoring.
Compare Shotsy GLP-1 Tracker against every rival
All rivals in one side-by-side table — identity, store metrics, ratings & sentiment, and strategic intel — plus a head-to-head page for each.
The outtake for Shotsy GLP-1 Tracker
Strengths to defend, gaps to attack
Core Strengths
- Clinical-data visualization creates high switching costs
- Multi-medication scheduling addresses complex poly-pharmacy needs
Critical Frictions
- Subscription gate for core features drives churn
- Data loss incidents post-update erode user trust
Growth Levers
- Integration of milestone photo tracking for progress
- Expansion into non-GLP-1 chronic medication tracking
Market Threats
- AI-first competitors reducing manual logging friction
- Subscription-model backlash increasing churn to free alternatives
What are the next best moves?
Audit data persistence logic because data loss is a top-3 complaint → restore user trust
Data loss incidents are eroding trust in medical history records.
Trade-off: Pause the new photo-milestone feature sprint — data reliability is a higher retention priority.
Re-tier subscription gates because paywalling core charts is the #1 complaint → reduce churn
Users perceive the current subscription price as high for features they could replicate manually.
Trade-off: Delay the non-GLP-1 medication support rollout — fixing the core monetization funnel is critical.
A counter-intuitive read
The subscription-gate backlash is not a pricing problem but a value-perception failure: users feel the app is a utility, not a service, and the current paywall ignores that distinction.
Feature Gaps vs Competitors
- Barcode scanning (available in Lose It! but missing here)
- Psychological coaching (available in Noom but missing here)
Key Takeaways
Shotsy holds a strong category lead through specialized clinical-data visualization, but the recent subscription-gate friction and data-loss incidents threaten long-term retention, so the PM must prioritize data reliability and re-tier the monetization model to prevent churn to free alternatives.
Where Is It Heading?
Mixed Signals
The GLP-1 tracking market is consolidating, with generalist apps adding specialized modules to compete with niche tools like Shotsy. The app's future depends on whether it can maintain its clinical-data moat while resolving the technical instability that currently undermines its premium positioning.
Data loss incidents following the latest update erode trust, which directly increases churn risk for long-term users.
High international grossing ranks in emerging markets suggest strong demand for the specialized medication-level visualization feature.